StevenJayIsakoffMDPhD

Clinical Trials

• Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response Start of enrollment: 2007 Jun 01

  Completed

  Phase 2

• TOBI to Monitor Response to Neoadjuvant Therapy in Breast Cancer Start of enrollment: 2008 Aug 01

  Completed

  Not Applicable

• ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer Start of enrollment: 2009 Nov 01

  Active, not recruiting

  Phase 2

• Trastuzumab and Vinorelbine in Advanced Breast Cancer Start of enrollment: 2010 Nov 01

  Terminated

  Phase 2

• PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer Start of enrollment: 2010 Nov 01

  Completed

  Phase 1

• A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer Start of enrollment: 2012 Jun 13

  Completed

  Phase 2

• Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa Start of enrollment: 2012 Oct 01

  Active, not recruiting

  Phase 2

• A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors Start of enrollment: 2012 Nov 01

  Completed

  Phase 1

• T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Start of enrollment: 2013 May 01

  Active, not recruiting

  Phase 2

• Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer Start of enrollment: 2013 Sep 01

  Terminated

  Phase 2

• Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases Start of enrollment: 2014 Nov 01

  Completed

  Phase 2

• Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer Start of enrollment: 2016 Aug 01

  Active, not recruiting

  Phase 1

• An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer Start of enrollment: 2016 Oct 01

  Unknown status

  Phase 2

• Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer Start of enrollment: 2017 Mar 31

  Active, not recruiting

  Phase 2

• PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer Start of enrollment: 2017 Dec 12

  Active, not recruiting

  Phase 1

• A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy Start of enrollment: 2019 Feb 01

  Active, not recruiting

  Not Applicable

• Onvansertib + Paclitaxel In TNBC Start of enrollment: 2022 Sep 30

  Recruiting

  Phase 1, Phase 2

  Roles: Contact, Principal Investigator

• Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Start of enrollment: 2020 Dec 18

  Recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer Start of enrollment: 2021 Jul 21

  Recruiting

  Phase 2

  Roles: Contact, Principal Investigator

• Join now to see all